WithdrawnPhase 3NCT03773510
Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
Studying Leiomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Italian Sarcoma Group
- Principal Investigator
- Roberta Sanfilippo, MDFondazione IRCCS INT di Milano
- Intervention
- Trabectedin discontinuation(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2025
Study locations (15)
- A.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST, Meldola, FC, Italy
- Istituto Europeo di Oncologia, Milan, MI, Italy
- Istituto Clinico Humanitas, Rozzano, MI, Italy
- Centro di Riferimento Oncologico di Aviano, Aviano, PD, Italy
- Policlinico Universitario Campus Biomedico, Roma, RM, Italy
- Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
- Ospedale Gradenigo, Torino, TO, Italy
- Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, Italy
- Azienda ospedaliero Universitaria Careggi di Firenze, Florence, Italy
- Fondazione IRCCS INT Milano, Milan, Italy
- Policlinico Federico II, Naples, Italy
- Irccs Istituto Oncologico Veneto (Iov), Padua, Italy
- Ospedale Giaccone, Palermo, Italy
- Istituti Fisioterapici Ospitalieri di Roma, Roma, Italy
Collaborators
PharmaMar
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03773510 on ClinicalTrials.govOther trials for Leiomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07125183Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic LeiomyosarcomaUniversity of Colorado, Denver
- ENROLLING BY INVITATIONNANCT07405346A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized EfficacyUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE1NCT06957431Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaWashington University School of Medicine
- RECRUITINGPHASE2NCT07076186Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMSM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT06528769Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced LeiomyosarcomaGabriel Tinoco
- RECRUITINGPHASE2NCT06524583Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the TumourUNICANCER
- RECRUITINGPHASE2NCT06571734XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable LeiomyosarcomaNorthwestern University
- RECRUITINGPHASE1NCT06308419A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or DeletionsM.D. Anderson Cancer Center